Gilead to Donate Truvada to CDC to Help With HIV PrEP in US Gilead to Donate Truvada to CDC to Help With HIV PrEP in US
While the Trump administration praised the donation, activists maintained their call for a reduction in the cost of the antiviral treatment, now pegged at more than $20,000 a year.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 14, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Gilead to donate HIV meds to 200K people
The company is planning to donate Truvada to these patients for up to 11 years in a move meant to end the HIV epidemic. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 13, 2019 Category: Pharmaceuticals Source Type: news

Gilead, HHS chief announce donation of HIV prevention drug Truvada
Health and Human Services Secretary Alex M. Azar announced a deal this week for drugmaker Gilead Sciences to donate billions of dollars in HIV prevention drugs over the course of the next decade. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 10, 2019 Category: Consumer Health News Source Type: news

Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company ’ s motives. (Source: NYT Health)
Source: NYT Health - May 10, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Generic Brands and Products State of the Union Message (US) Gilead Sciences Inc United States Drugs (Pharmaceuticals) Source Type: news

Generic Version of Truvada Available in U.S. by Sept. 2020
THURSDAY, May 9, 2019 -- A generic version of the HIV preexposure prophylaxis (PrEP) drug Truvada will be available in the United States by September 2020, a year earlier than expected, according to Gilead Sciences. " Gilead reached an agreement with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2019 Category: Pharmaceuticals Source Type: news

'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong
In shout-down with Gilead management, groups say company's patent for Truvada — the only drug approved for preventing new HIV infections — should be stripped. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 8, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong
In shout-down with Gilead management, groups say company's patent for Truvada — the only drug approved for preventing new HIV infections — should be stripped. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 8, 2019 Category: American Health Authors: Ron Leuty Source Type: news

Trump ’ s Proposed Budget Undermines His H.I.V. Plan, Experts Say
Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle. (Source: NYT Health)
Source: NYT Health - March 13, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Federal Budget (US) Truvada (Drug) United States Politics and Government Medicaid Epidemics Medicare Trump, Donald J Drugs (Pharmaceuticals) Budgets and Budgeting Prices (Fares, Fees and Rates) Source Type: news

Global Health: Bit by Bit, Scientists Gain Ground on AIDS
The “ London patient, ” apparently cured of H.I.V. infection, has gotten all the attention. But other recently revealed advances are more likely to affect the immediate course of the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - March 9, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Tests (Medical) Drugs (Pharmaceuticals) Third World and Developing Countries Truvada (Drug) Epidemics Gilead Sciences Inc Africa Source Type: news

Global Health: Scientists Are Gaining Ground Against AIDS
The “ London patient, ” apparently cured of H.I.V. infection, has gotten all the attention. But other recently revealed advances are more likely to affect the immediate course of the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - March 9, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Tests (Medical) Drugs (Pharmaceuticals) Third World and Developing Countries Truvada (Drug) Epidemics Gilead Sciences Inc Africa Source Type: news

' Grappling' With the Value of Descovy for HIV PrEP'Grappling' With the Value of Descovy for HIV PrEP
A new study shows that Descovy for pre-exposure prophylaxis (PrEP) is noninferior to Truvada. But as the field moves toward treating those most at risk, some question how much it matters.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Truvada Meets Its Match for PrEP
(MedPage Today) -- Placebo-less DISCOVER trial marks " dawn of a new age of prevention studies " (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 7, 2019 Category: Infectious Diseases Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2019 Category: Drugs & Pharmacology Source Type: news

Facing Legal Action, Insurer Now Will Cover People Taking Truvada, an H.I.V.-Prevention Drug
Regulators had accused Mutual of Omaha of denying policies to applicants, mostly gay men, who took medication to protect against the infection. (Source: NYT Health)
Source: NYT Health - January 11, 2019 Category: Consumer Health News Authors: GINA KOLATA Tags: Discrimination Truvada (Drug) Health Insurance and Managed Care Disability Insurance Homosexuality and Bisexuality Acquired Immune Deficiency Syndrome Infections Consumer Protection Suits and Litigation (Civil) Centers for Disease Contro Source Type: news

Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Task Force Calls for Offering PrEP to All at High Risk for H.I.V.
The recommendation would include all men and women whose sexual behavior, sex partners or drug use place them at high risk of contracting the virus that causes AIDS. (Source: NYT Health)
Source: NYT Health - November 20, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Condoms Preventive Medicine Drugs (Pharmaceuticals) Sex Minorities Source Type: news

This Is the Best Way to Prevent HIV, Expert Group Says
While there is no vaccine yet to protect against HIV, doctors have an effective drug to prevent HIV infection. After impressive studies overseas and in the U.S., the Food and Drug Administration approved Truvada, a combination of anti-HIV drugs, in 2012 as the first medication that can prevent healthy people from getting infected with HIV by up to 90%. Now, for the first time, a group of independent experts convened by the government, the U.S. Preventive Services Task Force (USPSTF), is recommending that people at high risk of acquiring HIV infection be prescribed the drug, also known as pre-exposure prophylaxis (PrEP). Th...
Source: TIME: Health - November 20, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized hiv-aids Source Type: news

Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2018 Category: Drugs & Pharmacology Source Type: news

Rare HIV PrEP Failure Reported in San Francisco
(MedPage Today) -- Truvada for pre-exposure prophylaxis remains highly effective, experts say (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 11, 2018 Category: Primary Care Source Type: news

Pre-Exposure Prophylaxis Not Tied to Drug Resistance Pre-Exposure Prophylaxis Not Tied to Drug Resistance
HIV-negative men who receive pre-exposure prophylaxis (PrEP) with tenofovir (TDF) and emtricitabine (FTC) do not develop resistance to these drugs, according to new findings from the IPERGAY ANRS trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 21, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Study shows PrEP effective at stopping HIV infections
Gilead's drug Truvada, used in conjunction with pre-exposure prophylaxis, can reduce HIV infection rates, a study has found. That's important news for regions of the U.S. like the South, where infection rates are high and continuing to rise. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 20, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Study shows PrEP effective at stopping HIV infections
Gilead's drug Truvada, used in conjunction with pre-exposure prophylaxis, can reduce HIV infection rates, a study has found. That's important news for regions of the U.S. like the South, where infection rates are high and continuing to rise. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

New Single-pill Combo Effective Against HIV-1 New Single-pill Combo Effective Against HIV-1
A new fixed-dose combination of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) is noninferior to fixed-dose efavirenz/emtricitabine/TDF (EFV/FTC/TDF) in treatment-naive adults with HIV-1 infection, according to results from the DRIVE-AHEAD trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2018 Category: Drugs & Pharmacology Source Type: news

Drugs show more promise for preventing HIV infections
Drug combo, sold as Truvada, "if widely implemented, theoretically could end the epidemic," says a top U.S. health official (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 24, 2018 Category: Consumer Health News Source Type: news

AIDS drugs show more promise for preventing infections
Drug combo, sold as Truvada, "if widely implemented, theoretically could end the epidemic," says a top U.S. health official (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 24, 2018 Category: Consumer Health News Source Type: news

FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide -... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2018 Category: Drugs & Pharmacology Source Type: news

Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV Fixed-Dose Bictegravir-Emtricitabine-Tenofovir Maintains Virologic Suppression in HIV
Fixed-dose bictegravir-emtricitabine-tenofovir (Biktarvy) maintains virologic suppression in adults with HIV-1 who are switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens, according to results from two noninferiority trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Truvada for Teens;'Unrealistic' Ebola Vax;'Safer' HIV Drug Lawsuit
(MedPage Today) -- News and commentary from the world of infectious diseases (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 16, 2018 Category: American Health Source Type: news

FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2018 Category: Drugs & Pharmacology Source Type: news

EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy EMA Panel Recommends Once-Daily HIV-1 Treatment Biktarvy
EMA panel recommends marketing authorization for a once-daily HIV-1 combo containing bictegravir, emtricitabine, and tenofovir.International Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 27, 2018 Category: Internal Medicine Tags: HIV/AIDS News Alert Source Type: news

No Higher Risk for Adverse Birth Outcomes with 3-Drug HIV Tx (CME/CE)
(MedPage Today) -- Tenofovir, emtricitabine, and ritonavir-boosted lopinavir compared with other ART (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 25, 2018 Category: OBGYN Source Type: news

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
WEDNESDAY, April 25, 2018 -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2018 Category: Pharmaceuticals Source Type: news

Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV
In HIV patients, combination therapy with tenofovir alafenamide and emtricitabine is non-inferior to that of abacavir plus lamivudine, according to a manufacturer-sponsored trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Monthly News Roundup - February 2018
Gilead ’s Biktarvy Cleared for Use in HIV-1 Infection In February, the FDA approved Gilead's Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide, or BIC/FTC/TAF), a combination, once-daily, oral treatment for HIV-1 infection in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2018 Category: Pharmaceuticals Source Type: news

New York Will Investigate Reports of Gay Men Denied Insurance
Denying men life or disability policies because they take drugs to prevent H.I.V. is discriminatory and may trigger penalties. (Source: NYT Health)
Source: NYT Health - February 15, 2018 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Discrimination Homosexuality and Bisexuality Truvada (Drug) Insurance GLBTQ Legal Advocates and Defenders (GLAD) New York Times New York State Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

He Took a Drug to Prevent AIDS. Then He Couldn ’ t Get Disability Insurance.
Insurers have denied life and disability coverage to men taking Truvada to prevent H.I.V. infection, say gay rights advocates and medical experts. (Source: NYT Health)
Source: NYT Health - February 12, 2018 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Discrimination Homosexuality and Bisexuality Life Insurance GLBTQ Legal Advocates and Defenders (GLAD) PrEP (pre-exposure prophylaxis) Mutual of Omaha Source Type: news

New 3-Drug Combo for HIV OK'd
(MedPage Today) -- Gilead's Biktarvy includes bictegravir, emtricitabine, and tenofovir alafenamide (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 8, 2018 Category: Primary Care Source Type: news

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

'We dropped the ball': Some Indigenous people had access to HIV drug for years without knowing
Truvada has been free for registered First Nations and Inuit people in B.C. for at least three years. (Source: CBC | Health)
Source: CBC | Health - January 3, 2018 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

Global Health: Six Lessons in Helping African Women Avoid H.I.V.
Countering the bleak history of AIDS prevention in Africa, a nonprofit explains how it helped women hide H.I.V. prevention pills and deflect male anger. (Source: NYT Health)
Source: NYT Health - December 16, 2017 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Women and Girls Acquired Immune Deficiency Syndrome Sex Truvada (Drug) Foreign Aid Africa Kenya Source Type: news

HIV Prevention Trials Network (HPTN) announces initiation of HPTN 084
(FHI360) The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2017 Category: International Medicine & Public Health Source Type: news

Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 20, 2017 Category: Pharmaceuticals Source Type: news

HIV prevention drug could save NHS £1 billion over 80 years
Conclusion Evidence to support the use of Prep is building. Studies have shown that it is very effective at reducing the chances of becoming infected with HIV, for men at risk of infection through unprotected sex with men. The question is more about the cost of treatment – and who should fund it – than whether it works. NHS England previously went to court to say that it should not be responsible for funding Prep, as it is a preventive treatment, and therefore should come under health promotion budgets held by local authorities. The High Court ruled that the NHS was able to fund the drug. NHS England has since ...
Source: NHS News Feed - October 19, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2017 Category: Pharmaceuticals Source Type: news

Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news